Program
bofanglutide
Also written as “GZR18”, “GZR18 injection” and “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive, led by 2 companies.
Drug pageBofanglutide: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gan & Lee Pharmaceuticalsits history only | 237 open or running | phase 3since Dec 5, 2024 | Feb 25, 2022 | Jun 30, 2027phase 3 · NCT07150975 |
| Carnot Laboratoriesits history only | 22 open or running | phase 3since May 24, 2026 | May 24, 2026 | Oct 2027phase 3 · NCT07628985 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Feb 25, 2022.
- Feb 5, 20244 phase 2 studiesGan & Lee Pharmaceuticals · NCT06256562, NCT06256549, NCT06256536 and 1 more
- Feb 29, 2024Named bofanglutideINNProposed as its International Nonproprietary Name in WHO's List 130
- Aug 8, 20243 phase 1 studiesGan & Lee Pharmaceuticals · NCT06554054, NCT06548997, NCT06548945
- Oct 29, 2024Phase 1 study in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT06670209 · 32 planned
- Dec 5, 2024Phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT06728124 · 640 enrolled · China
- Dec 16, 2024Phase 2 study in ObesityGan & Lee Pharmaceuticals · NCT06737042 · 326 enrolled · United States
- Jan 3, 20252 phase 3 studies in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT06778967, NCT06777238
- Jun 27, 2025Phase 2 study in Diabetes Mellitus, Type 2Gan & Lee Pharmaceuticals · NCT07055386 · 90 enrolled · China
- Jul 9, 2025Phase 1 study in OverweightGan & Lee Pharmaceuticals · NCT07119450 · 6 enrolled · China
- Aug 6, 20253 phase 1 studies in ObesityGan & Lee Pharmaceuticals · NCT07128888, NCT07141030, NCT07144098
- Aug 27, 2025Phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT07150975 · 420 planned · China
- Nov 20, 2025Phase 3 study in OverweightGan & Lee Pharmaceuticals · NCT07292441 · 224 enrolled · China
- Jan 5, 2026Phase 1 study in Obesity&T2DGan & Lee Pharmaceuticals · NCT07355738 · 266 enrolled · China
- Mar 20, 20262 phase 3 studies in Sleep Apnea, ObstructiveGan & Lee Pharmaceuticals · NCT07493057, NCT07501832
- May 24, 2026Carnot Laboratories’ first studies: 2 phase 3 studiesNew to Carnot LaboratoriesCarnot Laboratories · NCT07628985, NCT07622810
Ahead
- Jun 30, 2027Primary completion: phase 3 study in ObesityGan & Lee Pharmaceuticals · NCT07150975
- Oct 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Carnot Laboratories · NCT07628985
- Nov 14, 2027Primary completion: phase 3 study in Sleep Apnea, ObstructiveGan & Lee Pharmaceuticals · NCT07493057
- Dec 2027Primary completion: phase 3 study in ObesityCarnot Laboratories · NCT07622810
TargetBeta
“Bofanglutide (GZR18) is a long-acting GLP-1 receptor agonist administered by subcutaneous injection every 2 weeks.”study text, by rule · the study
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07628985Diabetes Mellitus, Type 2 · Mexico | 3 | Not yet recruiting | Carnot Laboratories | Oct 2027 | 374 |
| NCT07622810Obesity · Mexico | 3 | Not yet recruiting | Carnot Laboratories | Dec 2027 | 352 |
| NCT07501832Sleep Apnea, Obstructive · China | 3 | Recruiting | Gan & Lee Pharmaceuticals | Sep 28, 2028 | 140 |
| NCT07493057Sleep Apnea, Obstructive · China | 3 | Recruiting | Gan & Lee Pharmaceuticals | Nov 14, 2027 | 140 |
| NCT07355738Obesity&T2D · China | 1 | Completed | Gan & Lee Pharmaceuticals | May 22, 2026 | 266 |
| NCT07292441Overweight · China | 3 | Completed | Gan & Lee Pharmaceuticals | Sep 22, 2026 | 224 |
| NCT07150975Obesity · China | 3 | Recruiting | Gan & Lee Pharmaceuticals | Jun 30, 2027 | 420 |
| NCT07144098Obesity · China | 1 | Completed | Gan & Lee Pharmaceuticals | Apr 7, 2026 | 24 |
| NCT07141030Obesity · China | 1 | Completed | Gan & Lee Pharmaceuticals | Oct 20, 2025 | 32 |
| NCT07128888Obesity · China | 1 | Completed | Gan & Lee Pharmaceuticals | Apr 13, 2026 | 60 |
| NCT07119450Overweight · China | 1 | Completed | Gan & Lee Pharmaceuticals | Aug 13, 2025 | 6 |
| NCT07055386Diabetes Mellitus, Type 2 · China | 2 | Active, not recruiting | Gan & Lee Pharmaceuticals | Jun 28, 2026 | 90 |
| NCT06777238Diabetes Mellitus, Type 2 · China | 3 | Completed | Gan & Lee Pharmaceuticals | Jul 30, 2026 | 274 |
| NCT06778967Diabetes Mellitus, Type 2 · China | 3 | Completed | Gan & Lee Pharmaceuticals | Sep 18, 2026 | 1,133 |
| NCT06737042Obesity · United States | 2 | Completed | Gan & Lee Pharmaceuticals | Feb 27, 2026 | 326 |
| NCT06728124Obesity · China | 3 | Completed | Gan & Lee Pharmaceuticals | Mar 26, 2026 | 640 |
| NCT06670209Diabetes Mellitus, Type 2 | 1 | Not yet recruiting | Gan & Lee Pharmaceuticals | Mar 19, 2025 | 32 |
| NCT06554054Diabetes Mellitus, Type 2 · China | 1 | Active, not recruiting | Gan & Lee Pharmaceuticals | Dec 9, 2024 | 92 |
| NCT06548997Diabetes Mellitus, Type 2 · China | 1 | Completed | Gan & Lee Pharmaceuticals | Oct 20, 2022 | 57 |
| NCT06548945Overweight · China | 1 | Completed | Gan & Lee Pharmaceuticals | Aug 14, 2023 | 16 |
| NCT06256562Obesity · China | 2 | Completed | Gan & Lee Pharmaceuticals | Jun 5, 2024 | 340 |
| NCT06256549Diabetes Mellitus, Type 2 · China | 2 | Active, not recruiting | Gan & Lee Pharmaceuticals | Jul 20, 2024 | 272 |
| NCT06256536Obesity · China | 2 | Completed | Gan & Lee Pharmaceuticals | Oct 22, 2023 | 60 |
| NCT06256523Diabetes Mellitus, Type 2 · China | 2 | Completed | Gan & Lee Pharmaceuticals | Sep 28, 2023 | 72 |
| NCT05328726Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gan & Lee Pharmaceuticals | Feb 9, 2023 | 24 |
How it is read
Names in the registry
- “GZR18”, 13 entries
- “GZR18 injection”, 8 entries
- “GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets”, 1 entry
- “GZR18 injection A”, 1 entry
- “GZR18 injection B”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 13 studies
- Diabetes Mellitus, Type 2, 10 studies
- Sleep Apnea, Obstructive, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.